Commentary|Videos|June 24, 2025
Outcomes With Obe-Cel in ALL: An Age-Based Analysis of the FELIX Trial
Author(s)Bijal Shah, MD, MS, Jae Park, MD
Fact checked by: Chris Ryan
Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5